Literature DB >> 6617063

Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.

C Y Sum, A Yacobi, R Kartzinel, H Stampfli, C S Davis, C M Lai.   

Abstract

Esmolol is an ultra-short-acting beta blocker. Its kinetics was studied in eight healthy subjects after continuous intravenous infusion of 400 micrograms/kg/min over 2 hr. The concentrations of esmolol and its major metabolite, 3-[4-(2-hydroxy-3-[isopropylamino]propoxy)phenyl]propionic acid, in blood and urine were determined by gas chromatographic-mass spectrometric assay and HPLC. The distribution and elimination t1/2s of esmolol averaged 2.03 and 9.19 min. The apparent volume of distribution of esmolol averaged 3.43 l/kg and was four times the volume of the central compartment. The total clearance of esmolol averaged 285 ml/min/kg, indicating that nonhepatic routes play a predominant role in its clearance. The t1/2s of formation and elimination of the metabolite averaged 2.82 min and 3.72 hr. The ratio of the metabolite formation and elimination rate constants of the parent drug (kf/k10) averaged 0.829, suggesting that 82.9% of esmolol was converted to the metabolite (which is consistent with the urinary recovery of 71% of the dose as unconjugated metabolite). The volume of distribution and total clearance of the metabolite averaged 0.411 l/kg and 1.28 ml/min/kg. Esmolol was followed by a significant reduction of isoproterenol-induced increase in heart rate and systolic blood pressure at doses of 50, 150, and 400 micrograms/kg/min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617063     DOI: 10.1038/clpt.1983.193

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

1.  The effects of a new ultra-short-acting beta-adrenergic blocker, ONO-1101, on cardiac function during and after cardiopulmonary bypass.

Authors:  I Ahmet; N Fukushima; Y Sawa; T Masai; K Kadoba; K Kagisaki; J C Chang; T Yamaguchi; H Matsuda
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Esmolol--just another beta blocker?

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Bolus administration of esmolol for the treatment of intraoperative myocardial ischaemia.

Authors:  D R Miller; R J Martineau
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

5.  Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.

Authors:  Ju Mizuno; Ikuto Yoshiya; Takeshi Yokoyama; Yoshitsugu Yamada; Hideko Arita; Kazuo Hanaoka
Journal:  Eur J Clin Pharmacol       Date:  2007-01-09       Impact factor: 2.953

6.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

Review 7.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.

Authors:  D Wiest
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

8.  Preventive and therapeutic effects of a beta adrenoreceptor agonist, dobutamine, in carrageenan-induced inflammatory nociception in rats.

Authors:  Tufan Mert; Berin Tugtag; Metin Kilinc; Elif Sahin; Hafize Oksuz; Yasemin Gunes
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

9.  The antinociceptive effect of esmolol.

Authors:  Yoon Hee Kim
Journal:  Korean J Anesthesiol       Date:  2010-09-20

10.  Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.

Authors:  Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.